Feb 22, 2023

Wed Feb 22 14:02:21 UTC 2023 | 2 uur geledenEconomie Dit is een origineel bericht van PR Newswire ALAMEDA, Calif., Feb. 22, 2023 /PRNewswire/ -- AllCells®, a Discovery Life Sciences(TM) company and leading provider of critical starting material and services for cell and gene therapy (CGT), has announced the expansion of its apheresis network with the addition of two new centers in Houston, Texas, and Huntsville, Alabama. These new centers complement AllCells' existing presence in two major U.S. biotechnology hubs - the San Francisco Bay and Boston Metropolitan areas - further cementing its market-leading status and strengthening its ability to meet the growing worldwide demand for CGT products and services. AllCells is a recognized global service and quality leader due to its 99% deliverability rate and adherence to rigorous quality standards. With over 3,700 CGT-focused clinical trials underway globally, the company has invested significant resources to expand collection sites and increase its apheresis capacity to meet phase-appropriate requirements. In addition to its facilities expansion, AllCells has scaled its donor digital marketing, specialized recruiting, and event-hosting efforts, and also expanded its highly experienced project management team to support new and ongoing GMP projects. As a result, customers have access to tens of thousands of well-characterized, highly engaged, and recallable donors, coupled with in-house access to comprehensive analytical characterization, including cell biology, genomic, and proteomic capabilities. "This expansion is a key milestone for AllCells in our mission to become the most trusted global supplier of CGT solutions," said Danny Zheng, president of AllCells. "Our continued investments enable us to deliver to our customers a highly characterized supply chain through a single robust and scaled resource as they pursue important breakthroughs in the field of CGT." About AllCells Founded in 1998, AllCells, a Discovery Life Sciences company, is a market-leading provider of highly characterized primary cell and tissue products, supporting global biomedical organizations seeking to develop and manufacture novel drugs and cell therapies. By providing Clinical Grade and RUO products, custom donor management services, and integrated analytical capabilities, AllCells' comprehensive solutions streamline every stage of development to help bring novel therapies to market faster. Our FDA-registered, IRB-approved, AABB-compliant donor facilities strategically located across the U.S. provide access to healthy, recallable, well-characterized donors with diverse and rare demographics. Our adjacently located processing facilities enable immediate processing, cryopreservation, and a high degree of responsiveness to accommodate custom requests with exceptional quality and deliverability. Backed by over 30 years of combined scientific and regulatory expertise, AllCells is committed to providing flexible and scalable solutions necessary to dynamic, client-specific needs and timelines from inception to commercialization. AllCells - Science at your Service(TM) Logo - PR Newswire Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op. Andere persberichten van deze organisatie New study from Waltham Petcare Science Institute, part of Mars Petcare, shows cannabidiol (CBD) is effective at reducing stress in dog -- Single dose of THC-free CBD reduced stress in healthy dogs -- The study, conducted by the Waltham Petcare Science Institute, was published today in Frontiers in Veterinary Science. WALTHAM-ON-THE-WOLDS, England, Feb. 22, 2023 /PRNewswire/ -- Results from a study performed by the Waltham Petcare Science Institute published today shows a single oral dose (4 mgs per kg of body weight) of THC-free cannabidiol (CBD) can significantly relieve multip 2 uur geleden AllCells Expands Apheresis Network to Meet Rapid Growth in Demand for CELL AND GENE THERAPY Products and Services ALAMEDA, Calif., Feb. 22, 2023 /PRNewswire/ -- AllCells®, a Discovery Life Sciences(TM) company and leading provider of critical starting material and services for cell and gene therapy (CGT), has announced the expansion of its apheresis network with the addition of two new centers in Houston, Texas, and Huntsville, Alabama. These new centers complement AllCells' existing presence in two major U.S. biotechnology hubs - the San Francisco Bay and B 2 uur geleden UL Solutions Expands its ESG Advisory and Assurance Practice to Help Companies Navigate Growing Complexities From the initial mobilization of ESG initiatives through verification of environmental data and content, UL Solutions' expanded services will help guide companies throughout their ESG management journey. NORTHBROOK, Ill., Feb. 22, 2023 /PRNewswire/ -- UL Solutions, a global leader in applied safety science, today announced the launch of its expanded environmental, social and governance (ESG) advisory and assurance practice. This new practice will 2 uur geleden Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase TOKYO, Feb. 22, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity. In collaboration with researchers from the University of Shizuoka, Aji Bio-Pharma succeeded in developing a highly functional artificial RNA ligase usi 3 uur geleden The Chinese energy giant's new energy subsidiary has debuted at Genera in Spain MADRID, Feb. 22, 2023 /PRNewswire/ -- Genera Energy and Environment International Trade Fair 2023 ("Fair") begins in a grand opening ceremony at IFEMA in the capital of Spain, with the joint participation of new energy dealers, distributors, manufacturers and professionals from all around the world, to make influential global business cooperation and negotiation. On February 21, Jinneng Clean Energy Technology Ltd. (hereinafter referred to as "Ji 4 uur geleden CRT 2023 selects Syntach Cardiac Support System for Best Innovation Competition LUND, Sweden, Feb. 22, 2023 /PRNewswire/ -- Syntach AB ("Syntach") is pleased to announce that the Company's Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the Omni Shoreham Hotel in Washington DC, February 25 - 28, 2023. The Syntach technology also qualifies for the CRT 2023 Top Innovation Award. The winner ann 4 uur geleden